A-646 - Ph I/IIa dose finding study of Triplet regimen of Relatlimab (RELA) Ipilimumab (IPI) and NIvolumab (NIVO) in first line TherapY of metastatic melanoma (MM) (TRINITY)

EJC Skin Cancer · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles